




PATIENT NAME: Saf Hunter Shigeta	MRN: 1077823	VETERINARIAN:
SPECIMEN ID: 475956	DRAW DATE: 7-Mar-23	FACILITY:
SPECIES: Feline	RECEIVED DATE: 10-Mar-23	
GENDER: Female Spayed	REPORT DATE: 10-Mar-23	
AGE: 13.7	SAMPLE TYPE: Dried Serum - 2	PH:
WEIGHT: 13.61 lb	PATIENT STAGE: Apparently Healthy	FAX:
BREED: DSH	TREATMENT: unknown	


Relevant Context (provided on TRF)

<input type="checkbox"/> Corticosteroids	<input type="checkbox"/> Antibiotics	<input type="checkbox"/> Suspected Mass	<input type="checkbox"/> Hypercalcemia
<input type="checkbox"/> NSAIDs	<input type="checkbox"/> Anemia	<input type="checkbox"/> Enlarged Node	<input type="checkbox"/> B12 Deficiency
<input type="checkbox"/> Chemotherapy	<input checked="" type="checkbox"/> GI Signs	<input type="checkbox"/> Fever	<input type="checkbox"/> Known Disease



Intpretative Comment

Patient values for TK1 and HPT are above the critical thresholds. Both TK1 and HPT have significantly increased from prior and may be indicative of developing cancer. Patient should be evaluated for source. If the patient is on corticosteroids, other anti-inflammatory medication, or has uncontrolled Cushings, it can suppress HPT.



Additional Reviewer Comments - need consult? email consult@vdi lab.com

Code 3255.2

All comments are general in nature and in absence of detailed knowledge of patient status or treatment.
For case-specific consultations, please contact VDI.

Reviewer: RR

Patient Monitoring Provides Guidance




Thymidine Kinase, type 1 (TK1) is a DNA proliferation enzyme and is elevated in dividing cancer cells. During therapy (chemo/surgery) the source of TK1 is reduced/eliminated and serum TK1 (sTK1) levels will fall. Conversely, growing cancer cells during disease recurrence will increase sTK1 levels. Suspected undiagnosed patients can also be followed in the same manner. This makes the Cancer Panel an effective tool for patient monitoring. **Need Consultation? email consult@vdiilab.com**

INTERPRET THE REPORT

VDI Cancer Panel monitoring reports come with a number of important indicators. Use the key below to interpret what the results mean in context with your patient.




Significant Change

a change of 40% or more from prior. Studies show this level of change can precede cancer recurrence.

Indicator	What does it signify?	What does it mean?
	Significant reduction or improvement of at least 40% over previous	Indicates therapy is effective in reducing or eliminating the tumor or inflammation
TK1 Only 	Significant increase in TK1 however TK1 remains below the 9U/L threshold	Indicates the level of change is worth watching – changes in clinical status of the patient is important
	Significant increase in the biomarker above critical thresholds	Studies show this level of change in TK1 often precedes cancer recurrence, or is consistent with malignant tumor growth.

Trending

2 or more data points in the same direction. Short-term trending events are the most valuable in confirming cancer recurrence.

Indicator	What does it signify?	What does it mean?
	Significant trend of 2 or more data points in the reduction or improvement of biomarker	Downward trending provides confirmation of effective therapy
	2 data points in the same direction of high biomarker levels	Upward trending has high probability of disease recurrence (TK1) or growing inflammation (CRP/HPT) and requires immediate intervention with either a change in therapy or rescue therapy
	3 data points in the same direction of high biomarker levels	

RETEST WINDOW

Depending upon the type of cancer different monitoring intervals are recommended (see below). Use the chart below to identify appropriate retest window for this patient. These windows may be adjusted by the presence of clinical signs or elevated CAR (CRP/Albumin Ratio). Repeat tests within 6 months of previous automatically receive a discounted rate.

Monitoring Purpose	Retest Window	Notes
Developing Disease, but unconfirmed		Retest window is recommended based on common applications absent any context. For more case-specific guidelines, email: consult@vdiilab.com
Lymphoma, HSA, fast cancers	Apr 04 - Apr 18	
Solid Tumors, slow/indolent cancers	May 06 - Jul 05	
Therapeutic Monitoring		
Lymphoma, HSA, fast cancers	Apr 04 - Apr 18	
Solid Tumors, slow/indolent cancers	May 06 - Jul 05	
Remission Monitoring		
Lymphoma, HSA, fast cancers	Apr 04 - Apr 18	
Solid Tumors, slow/indolent cancers	May 06 - Jul 05	
Mass Removal/Metastatic Disease	Apr 04 - Apr 18	